2018
DOI: 10.1016/j.ihj.2017.06.016
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The use of Absorb BVS in this real-world experience was associated with very good immediate and medium-term clinical outcomes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 11 publications
1
1
0
Order By: Relevance
“…17 Interestingly, it seems that, in this study, diabetes mellitus did not contribute to the inferior clinical outcome in these patients because its incidence of 33.3 % was comparable with other studies that showed a lower MACE rate. [31][32][33] Also, the prevalence of stable and unstable angina at the baseline (57.1 % and 31.0 %, respectively) in treated patients was similar to the available data from the ABSORB III and ABSORB EXTEND clinical trials. 17,33 Relating to the lesion characteristics in the current study, bifurcations lesions were present in 16.7 %.…”
Section: Discussionsupporting
confidence: 77%
See 1 more Smart Citation
“…17 Interestingly, it seems that, in this study, diabetes mellitus did not contribute to the inferior clinical outcome in these patients because its incidence of 33.3 % was comparable with other studies that showed a lower MACE rate. [31][32][33] Also, the prevalence of stable and unstable angina at the baseline (57.1 % and 31.0 %, respectively) in treated patients was similar to the available data from the ABSORB III and ABSORB EXTEND clinical trials. 17,33 Relating to the lesion characteristics in the current study, bifurcations lesions were present in 16.7 %.…”
Section: Discussionsupporting
confidence: 77%
“…However, in the previous studies, few patients with biomarker-positive acute coronary syndromes were enrolled and the rates of prior PCI were much lower, ranging from 1.4 % to 9.2 %. 31,32 Besides, it was shown in the ABSORB III trial that prior coronary interventions were the independent predictor of device-related adverse events, particularly device thrombosis. 17 Interestingly, it seems that, in this study, diabetes mellitus did not contribute to the inferior clinical outcome in these patients because its incidence of 33.3 % was comparable with other studies that showed a lower MACE rate.…”
Section: Discussionmentioning
confidence: 99%